X. Addition to the Points to Consider of the NIH Guidelines Regarding 
the Safety of Delivery/Expression Systems and Report on Murine RCR 
Assays/Dr. Miller 43 
XI. Addition to the Points to Consider of the NIH Guidelines Regarding 
Procedures for Expedited Review of Human Gene Transfer Protocols 46 
XII. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene 
Therapy Protocol Entitled: A Phase I Study of Gene Therapy of Cystic 
Fibrosis Utilizing a Replication Deficient Recombinant Adenovirus 
Vector to Deliver the Human Cystic Fibrosis Transmembrane Conductance 
Regulator cDNA to the Airways /Drs. Wilmott, Whitsett, and Trapnell 51 
XIII. Addition to Appendix D of the NIH Guidelines Regarding a Human Gene 
Transfer Protocol Entitled: Gene Transfer for Cystic Fibrosis Using 
El Deleted Adenovirus: A Phase I Trial in the Nasal Cavity /Dr. Boucher 
and Knowles 59 
XIV. Proposed Addition to Appendix of the NIH Guidelines Regarding a Human 
Gene Therapy Protocol Entitled: Phase I Study of Transfected Cancer 
Cells Expressing the IL-2 Gene Product in Limited Stage Small-Cell 
Lung Cancer /Dr. Cassileth 66 
XV. Proposed Addition to Appendix D of the NIH Guidelines Regarding 
a Human Gene Therapy Protocol Entitled: Use of Safety-Modified 
Retroviruses to Introduce Chemotherapy Resistance Sequences into 
Normal Hematopoietic Stem Cells for Chemoprotection During the 
Therapy of Ovarian Cancer /Dr. Deisseroth 70 
XVI. Addition to the Points to Consider of the NIH Guidelines Regarding 
Procedures for Expedited Review of Human Gene Transfer Protocols 
(Continued) 73 
XVII. Discussion Regarding the Human Gene Transfer Protocol Materials 
Submitted for Approval on a Compassionate Use Basis/Drs. Royston and 
Sobol 77 
XVIII. Adjournment 82 
Attachment - Roster 
[58] 
Recombinant DNA Research, Volume 17 
